Alector, Inc. ALEC
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2019 · data as of November 13, 2026
Alector, Inc. (ALEC) is a healthcare company listed in the US with a market value of about $378M. In the twelve months to September 30, 2026 it had revenue of $173M and net income of $41M, a net margin of 23.9%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).
Key numbers: a P/E of 7.3, 5-year revenue growth of -0% a year, a 5-year average ROIC of -74%.
About Alector
Alector is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2019. Revenue went from $4M in 2017 to $21M in 2025, growth of about 24.1% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 25% over three years (dilution for shareholders). It spends 585% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $173M | $21M | $101M | $97M | $134M | $207M | $21M | $21M | $28M | $4M |
| Net income | $41M | -$143M | -$119M | -$130M | -$133M | -$36M | -$190M | -$105M | -$52M | -$32M |
| Free cash flow | -$150M | -$184M | -$231M | -$187M | -$24M | $295M | -$172M | -$115M | $126M | -$19M |
| EPS (diluted) | $0.35 | $-1.39 | $-1.23 | $-1.56 | $-1.62 | $-0.45 | $-2.45 | $-1.71 | $-4.62 | $-3.55 |
| Net margin | 23.9% | -679.2% | -118.4% | -134.3% | -99.8% | -17.5% | -901.6% | -496.6% | -188.8% | -869.6% |
| ROIC | — | -183.4% | -67.4% | -69.3% | -42.2% | -8.5% | -48.4% | -37.2% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $4.42, 74% above the current price; targets range from $1.00 to $8.00; the consensus rating is “Buy”; expected EPS is $0.89 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Alector’s P/E ratio?
About 7.3, based on the last twelve months of diluted earnings per share.
Does Alector pay a dividend?
Not currently.
Is Alector a good stock to buy?
We do not give buy or sell advice. Alector scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.